Shabnam Shalapour, Ph.D.

Peer-Reviewed Articles

1. Hao D, Han G, Sinjab A, Gomez-Bolanos LI, Lazcano R, Serrano A, Hernandez SD, Dai E, Cao X, Hu J, Dang M, Wang R, Chu Y, Song X, Zhang J, Parra ER, Wargo JA, Swisher SG, Cascone T, Sepesi B, Futreal AP, Li M, Dubinett SM, Fujimoto J, Solis Soto LM, Wistuba II, Stevenson CS, Spira A, Shalapour S, Kadara H, Wang L. The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma. Cancer Discov. e-Pub 2022. PMID: 36098652.
2. Karin M, Shalapour S. Regulation of antitumor immunity by inflammation-induced epigenetic alterations. Cell Mol Immunol 19(1):59-66, 2022. e-Pub 2021. PMID: 34465885.
3. Li J, Ma X, Chakravarti D, Shalapour S, DePinho RA. Genetic and biological hallmarks of colorectal cancer. Genes Dev 35(11-12):787-820, 2021. PMID: 34074695.
4. Shalapour S, Karin M. The neglected brothers come of age: B cells and cancer. Semin Immunol 52:101479, 2021. e-Pub 2021. PMID: 34215491.
5. Zhou Y, Bastian IN, Long MD, Dow M, Li W, Liu T, Ngu RK, Antonucci L, Huang JY, Phung QT, Zhao XH, Banerjee S, Lin XJ, Wang H, Dang B, Choi S, Karin D, Su H, Ellisman MH, Jamieson C, Bosenberg M, Cheng Z, Haybaeck J, Kenner L, Fisch KM, Bourgon R, Hernandez G, Lill JR, Liu S, Carter H, Mellman I, Karin M, Shalapour S. Activation of NF-κB and p300/CBP potentiates cancer chemoimmunotherapy through induction of MHC-I antigen presentation. Proc Natl Acad Sci U S A 118(8), 2021. PMID: 33602823.
6. Todoric J, Di Caro G, Reibe S, Henstridge DC, Green CR, Vrbanac A, Ceteci F, Conche C, McNulty R, Shalapour S, Taniguchi K, Meikle PJ, Watrous JD, Moranchel R, Najhawan M, Jain M, Liu X, Kisseleva T, Diaz-Meco MT, Moscat J, Knight R, Greten FR, Lau LF, Metallo CM, Febbraio MA, Karin M. Fructose stimulated de novo lipogenesis is promoted by inflammation. Nat Metab:1034-1045, 2020.
7. Ryan ST, Zhang J, Burner DN, Liss M, Pittman E, Muldong M, Shabaik A, Woo J, Basler N, Cunha J, Shalapour S, Estrada MV, Karin M, Messer K, Howell S, Kane CJ, Jamieson. Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. CAM. J Transl Med:214, 2020.
8. Lichtenstern CR, Ngu RK, Shalapour S, Karin M.. Immunotherapy, Inflammation and Colorectal Cancer. Cells 26(38):649-671, 2020.
9. Shalapour S, Karin M. Cruel to Be Kind: Epithelial, Microbial, and Immune Cell Interactions in Gastrointestinal Cancers. Annual Review Immunol, 2020.
10. Wang M, Jarmusch AK, Vargas F, Aksenov AA, Gauglitz JM, Weldon K, Petras D, da Silva R, Quinn R, Melnik AV, van der Hooft JJJ, Caraballo-Rodríguez AM, Nothias LF, Aceves CM, Panitchpakdi M, Brown E, Di Ottavio F, Sikora N, Elijah EO, Labarta-Bajo L, Gentry EC, Shalapour S, Kyle KE, Puckett SP, Watrous JD, Carpenter CS, Bouslimani A, Ernst M, Swafford AD, Zúñiga EI, Balunas MJ, Klassen JL, Loomba R, Knight R, Bandeira N, Dorrestein. PC.Mass spectrometry searches using MASST. Nat Biotechnol:23-26, 2020.
11. Shalapour S, Karin M. Pas de Deux. Pas de Deux: Control of Anti-tumor Immunity by Cancer-Associated Inflammation. Immunity 51:15-26, 2019.
12. Febbraio MA, Reibe S, Shalapour S, Ooi GJ, Watt MJ, Karin M. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?. Cell Metab:18-26, 2019.
13. Dow M, Pyke RM, Tsui BY, Alexandrov LB, Nakagawa H, Taniguchi K, Seki E, Harismendy O, Shalapour S, Karin M, Carter H, Font-Burgada J. Integrative genomic analysis of mouse and human hepatocellular carcinoma. Proc Natl Acad Sci U S A 115(42):42, 2018. e-Pub 2018. PMID: 30287485.
14. Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, Downes M, Yu RT, Evans RM, Dorrestein PC, Knight R, Benner C, Anstee QM, Karin M. Author Correction: Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 561(7721):E1, 2018. PMID: 29973714.
15. Zhong Z, Liang S, Sanchez-Lopez E, He F, Shalapour S, Lin XJ, Wong J, Ding S, Seki E, Schnabl B, Hevener AL, Greenberg HB, Kisseleva T, Karin M. New mitochondrial DNA synthesis enables NLRP3 inflammasome activation. Nature 560(7717):198-203, 2018. e-Pub 2018. PMID: 30046112.
16. Dhar D, Antonucci L, Nakagawa H, Kim JY, Glitzner E, Caruso S, Shalapour S, Yang L, Valasek MA, Lee S, Minnich K, Seki E, Tuckermann J, Sibilia M, Zucman-Rossi J, Karin M. Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell 33(6):1061-1077, 2018. PMID: 29894692.
17. Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, Downes M, Yu RT, Evans RM, Dorrestein PC, Knight R, Benner C, Anstee QM, Karin M. Erratum: Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 552(7685):430, 2017. e-Pub 2017. PMID: 29168501.
18. Shalapour S, Lin XJ, Bastian IN, Brain J, Burt AD, Aksenov AA, Vrbanac AF, Li W, Perkins A, Matsutani T, Zhong Z, Dhar D, Navas-Molina JA, Xu J, Loomba R, Downes M, Yu RT, Evans RM, Dorrestein PC, Knight R, Benner C, Anstee QM, Karin M. Inflammation-induced IgA+ cells dismantle anti-liver cancer immunity. Nature 551(7680):340-345, 2017. e-Pub 2017. PMID: 29144460.
19. Shalapour S, Karin M. Fatty Acid-Induced T Cell Loss Greases Liver Carcinogenesis. Cell Metab 10(5):759-61, 2016. PMID: 27166937.
20. Zhong Z, Umemura A, Sanchez-Lopez E, Liang S, Shalapour S, Wong J, He F, Boassa D, Perkins G, Ali SR, McGeough MD, Ellisman MH, Seki E, Gustafsson AB, Hoffman HM, Diaz-Meco MT, Moscat J, Karin M. NF-B Restricts Inflammasome Activation via Elimination of Damaged Mitochondria. Cell:896-910, 2016.
21. Zhong Z, Umemura A, Sanchez-Lopez E, Liang S, Shalapour S, Wong J, He F, Boassa D, Perkins G, Ali SR, McGeough MD, Ellisman MH, Seki E, Gustafsson AB, Hoffman HM, Diaz-Meco MT, Moscat J, Karin M. NF-κB Restricts Inflammasome Activation via Elimination of Damaged Mitochondria. Cell 164(5):896-910, 2016. PMID: 26919428.
22. Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K, Levitzki A, Karin M. Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene:2634-44, 2016.
23. Shalapour S, Karin M. Immunity, inflammation and cancer: an eternal fight between good and evil. J Clin Invest 125(9):3347-55, 2015. e-Pub 2015. PMID: 26325032.
24. Font-Burgada J, Shalapour S, Ramaswamy S, Hsueh B, Rossell D, Umemura A, Taniguchi K, Nakagawa H, Valasek MA, Ye L, Kopp JL, Sander M, Carter H, Deisseroth K, Verma IM, Karin M. Hybrid Periportal Hepatocytes Regenerate the Injured Liver without Giving Rise to Cancer. Cell 162(4):766-79, 2015. PMID: 26276631.
25. Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D, Willimsky G, Ammirante M, Strasner A, Hansel DE, Jamieson C, Kane CJ, Klatte T, Birner P, Kenner L, Karin M. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 521(7550):94-8, 2015. e-Pub 2015. PMID: 25924065.
26. Wang k, Kim M, Di Caro G, Wong J, Shalapour S, Wan J, Zhang W, Chen S, Wu L, Taniguchi K, Feng Y, Fearon E, Grivennikov SI, and Karin M. Interleukin-17 receptor A signals in transformed enterocytes to promote early colorectal tumorigenesis. Immunity:1052-63, 2014.
27. Wang K, Kim MK, Di Caro G, Wong J, Shalapour S, Wan J, Zhang W, Zhong Z, Sanchez-Lopez E, Wu LW, Taniguchi K, Feng Y, Fearon E, Grivennikov SI, Karin M. Interleukin-17 receptor a signaling in transformed enterocytes promotes early colorectal tumorigenesis. Immunity 41(6):1052-63, 2014. e-Pub 2014. PMID: 25526314.
28. Ammirante M, Shalapour S, Kang Y, Jamieson C and Karin C.. Tissue injury and hypoxia promote malignant progression of prostate cancer through myofibroblast activation and CXCL13 induction. Proc Natl Acad Sci U S A:14776-81, 2014.
29. Ammirante M, Shalapour S, Kang Y, Jamieson CA, Karin M. Tissue injury and hypoxia promote malignant progression of prostate cancer by inducing CXCL13 expression in tumor myofibroblasts. Proc Natl Acad Sci U S A 111(41):14776-81, 2014. e-Pub 2014. PMID: 25267627.
30. Umemura A, Park EJ, Taniguchi K, Lee JH, Shalapour S, Valasek MA, Aghajan M, Nakagawa H, Seki E, Hall MN, Karin M. Liver damage, inflammation, and enhanced tumorigenesis after persistent mTORC1 inhibition. Cell Metab 20(1):133-44, 2014. e-Pub 2014. PMID: 24910242.
31. He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, Shalapour S, Seki E, Yost SE, Jepsen K, Frazer KA, Harismendy O, Hatziapostolou M, Iliopoulos D, Suetsugu A, Hoffman RM, Tateishi R, Koike K, Karin M. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL-6 signaling. Cell 155(2):384-96, 2013. PMID: 24120137.
32. Ammirante M, Kuraishy AI, Shalapour S, Strasner A, Ramirez-Sanchez C, Zhang W, Shabaik A, Karin M. An IKKα-E2F1-BMI1 cascade activated by infiltrating B cells controls prostate regeneration and tumor recurrence. Genes Dev 27(13):1435-40, 2013. e-Pub 2013. PMID: 23796898.
33. Bastian L, Hof J, Pfau M, Fichtner I, Eckert C, Henze G, Prada J, von Stackelberg A, Seeger K, Shalapour S. Synergistic activity of bortezomib and HDACi in preclinical models of B-cell precursor acute lymphoblastic leukemia via modulation of p53, PI3K/AKT, and NF-κB. Clin Cancer Res 19(6):1445-57, 2013. e-Pub 2013. PMID: 23357978.
34. Prada J, Shalapour S, Pfau M, Henze G, Seeger K. The serotonin receptor-antagonist ondansetron induces significant increases in the expression of interferon-gamma which correlate with antiproliferative properties in the acute lymphoblastic leukaemia cell line REH. Scand J Immunol:519-20, 2012.
35. Shalapour S, Deiser K, Kühl AA, Glauben R, Krug SM, Fischer A, Sercan O, Chappaz S, Bereswill S, Heimesaat MM, Loddenkemper C, Fromm M, Finke D, Hämmerling GJ, Arnold B, Siegmund B, Schüler T. Interleukin-7 links T lymphocyte and intestinal epithelial cell homeostasis. PLoS One 7(2):e31939, 2012. e-Pub 2012. PMID: 22384106.
36. Shalapour S, Hof J, Kirschner-Schwabe R, Bastian L, Eckert C, Prada J, Henze G, von Stackelberg A, Seeger K. High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse. Haematologica 96(11):1627-35, 2011. e-Pub 2011. PMID: 21828124.
37. Hof J, Krentz S, van Schewick C, Körner G, Shalapour S, Rhein P, Karawajew L, Ludwig WD, Seeger K, Henze G, von Stackelberg A, Hagemeier C, Eckert C, Kirschner-Schwabe R. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia. J Clin Oncol 29(23):3185-93, 2011. e-Pub 2011. PMID: 21747090.
38. Prada J, Shalapour S, Pfau M, Henze G, Seeger K. Antiproliferative effect of the serotonin receptor antagonist ondansetron in the acute lymphoblastic leukemia cell line REH. Acta Oncol 50(4):591-2, 2011. e-Pub 2010. PMID: 21091402.
39. Bastian L, Einsiedel HG, Henze G, Seeger K, Shalapour S.. The sequence of application of methotrexate and histone deacetylase inhibitors determines either a synergistic or an antagonistic response in childhood acute lymphoblastic leukemia cells. Leukemia:359-61, 2011.
40. Ziegelberger G, Baum C, Borkhardt A, Cobaleda C, Dasenbrock C, Dehos A, Grosche B, Hauer J, Hornhardt S, Jung T, Kammertoens T, Lagroye I, Lehrach H, Lightfoot T, Little MP, Rossig C, Sanchez-Garcia I, Schrappe M, Schuez J, Shalapour S, Slany R, Stanulla M and Weiss W. Research recommendations toward a better understanding of the causes of childhood leukemia. Blood Cancer Journal, 2011.
41. Czéh M, Loddenkemper C, Shalapour S, Schön C, Robine S, Goldscheid E, Stein H, Schüler T, Willimsky G, Blankenstein T. The immune response to sporadic colorectal cancer in a novel mouse model. Oncogene:6591-602, 2010.
42. Shalapour S, Deiser K, Sercan O, Tuckermann J, Minnich K, Willimsky G, Blankenstein T, Hämmerling GJ, Arnold B, Schüler T. Commensal microflora and interferon-gamma promote steady-state interleukin-7 production in vivo. Eur J Immunol 40(9):2391-400, 2010. PMID: 20690180.
43. Shalapour S, Eckert C, Seeger K, Pfau M, Prada J, Henze G, Blankenstein T, Kammertoens T. Leukemia-associated genetic aberrations in mesenchymal stem cells of children with acute lymphoblastic leukemia. J Mol Med (Berl) 88(3):249-65, 2010. e-Pub 2010. PMID: 20155409.
44. Giese A, Kirschner-Schwabe R, Blumchen K, Wronski L, Shalapour S, Prada J, Driever PH, Brauer M, Schuelke M, Henze G, Seeger K. Prenatal manifestation of pancytopenia in Pearson marrow-pancreas syndrome caused by a mitochondrial DNA deletion. Am J Med Genet A 143(3):285-8, 2007. PMID: 17219391.
45. Shalapour S, Zelmer A, Pfau M, Moderegger E, Costa-Blechschmidt C, van Landeghem FK, Taube T, Fichtner I, Bührer C, Henze G, Seeger K, Wellmann S. The thalidomide analogue, CC-4047, induces apoptosis signaling and growth arrest in childhood acute lymphoblastic leukemia cells in vitro and in vivo. Clin Cancer Res 12(18):5526-32, 2006. PMID: 17000689.